Mixed histiocytosis (Langerhans cell histiocytosis [LCH] / Erdheim-Chester disease [ECD]) developing after treatment for initial skull LCH is not well recognized. An elderly woman presented with ...
Members of the research team at the heavy ion gantry of the Heidelberg Ion-Beam Therapy Centre. Left to right: Simon Jolly, Joao Seco, Laurent Kelleter, Lennart Volz and Raffaella Radogna. (Courtesy: ...
(HealthDay)—Most dimensions of quality of life (QoL) are impaired in patients with relapsed/refractory multiple myeloma, and treatment may have mixed effects on QoL, according to a study published ...
London, UK. 10th June 2024 - Amber Therapeutics, a UK-based medical technology company developing a breakthrough adaptive neuromodulation therapy to treat mixed urinary incontinence (MUI), announces ...
The broader implementation of step therapy in Medicare Advantage could significantly influence the treatment access and experience as well as health outcomes for millions of patients with diverse ...
A retrospective multicenter study found that neurologic, cardiac, nutritional and frailty measures were largely maintained over at least 12 months of tafamidis treatment in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results